(Q83190512)
Statements
Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms (English)
Karin Hedenmalm
Cüneyt Güzey
Marja-Liisa Dahl